| Issue Date | Title | Author(s) |
| 2013-10-01 | High discordance rates between sub-areolar and peri-tumoural breast lymphoscintigraphy | Noushi, F; Spillane, AJ; Uren, RF; Cooper, R; Allwright, S; Snook, KL; Gillet, D; Pearce, AM; Gebski, V |
| 2016-10-01 | Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer | Parkinson, B; Viney, R; Haas, M; Goodall, S; Srasuebkul, P; Pearson, SA |
| 2017-06-01 | Financial cost of lymphedema borne by women with breast cancer | Boyages, J; Xu, Y; Kalfa, S; Koelmeyer, L; Parkinson, B; Mackie, H; Viveros, H; Gollan, P; Taksa, L |
| 1992-01-01 | A cost utility analysis of mammography screening in Australia | Hall, J; Gerard, K; Salkeld, G; Richardson, J |
| 2018-08-01 | Development and pilot testing of a Decision Aid (DA) for women with early-stage breast cancer considering contralateral prophylactic mastectomy | Ager, B; Jansen, J; Porter, D; Phillips, KA; Glassey, R; Rankin, N; Musiello, T; Boyle, F; Zdenkowski, N; Skandarajah, A; Saunders, C; Sundaresan, P; De Abreu Lourenco, R; Butow, P |
| 2018-06-01 | Cost-effectiveness of the BRECONDA decision aid for women with breast cancer: Results from a randomized controlled trial | Parkinson, B; Sherman, KA; Brown, P; Shaw, LKE; Boyages, J; Cameron, LD; Elder, E; Lam, T |
| 2007-06 | The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49. | Norman, RPA; Evans, DG; Easton, DF; Young, KC |
| 2017-01-01 | Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: Protocol detailing observations in a whole of population cohort | Daniels, B; Lord, SJ; Kiely, BE; Houssami, N; Haywood, P; Lu, CY; Ward, RL; Pearson, SA |
| 2012-11-22 | Chemotherapy administration: Modelling the costs of alternative protocols | Haywood, P; De Raad, J; Van Gool, K; Haas, M; Gallego, G; Pearson, SA; Faedo, M; Ward, R |
| 1996-01 | A comparison of two quality-of-life questionnaires for cancer clinical trials: the functional living index--cancer (FLIC) and the quality of life questionnaire core module (QLQ-C30). | King, MT; Dobson, AJ; Harnett, PR |
